BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//TrialSonar//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:TrialSonar · $NVS readouts
X-WR-CALDESC:Clinical-trial primary completion dates from ClinicalTrials.go
 v\, refreshed nightly by TrialSonar. Not investment advice.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06004661-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20261106
DTEND;VALUE=DATE:20261107
SUMMARY:AAA617 readout (P2) · Novartis Pharmaceuticals $NVS
DESCRIPTION:Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Partic
 ipants With Moderately and Severely Impaired and With Normal Renal Functio
 n\n\nPrimary completion date: 2026-11-06 (estimated)\nOriginally planned: 
 2026-03-20 (+7.6 months)\nPhase 2 · Oncology · Metastatic Castration-Res
 istant Prostate Cancer (mCRPC)\nEnrollment: 23 · Sites: 9\n\nPrimary comp
 letion = last participant's primary-endpoint data collected\; topline resu
 lts usually follow weeks to months later. Sponsor-reported\, often an esti
 mate. Not investment advice.\n\nhttps://datacutoff.com/radar.html?
 nct=NCT06004661\nhttps://clinicaltrials.gov/study/NCT06004661
URL:https://datacutoff.com/radar.html?nct=NCT06004661
CATEGORIES:Oncology,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06894511-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20261117
DTEND;VALUE=DATE:20261118
SUMMARY:PSMAndARPI readout (P2) · Novartis Pharmaceuticals $NVS
DESCRIPTION:An Open-label Study of Lutetium (177Lu) Vipivotide Tetraxetan (
 AAA617) in Combination With ARPI Versus AAA617 in PSMA Positive First-line
  mCRPC\n\nPrimary completion date: 2026-11-17 (estimated)\nOriginally plan
 ned: 2027-04-01 (-4.4 months)\nPhase 2 · Oncology · Metastatic Castratio
 n Resistant Prostate Cancer (mCRPC)\nEnrollment: 7 · Sites: 5\n\nPrimary 
 completion = last participant's primary-endpoint data collected\; topline 
 results usually follow weeks to months later. Sponsor-reported\, often an 
 estimate. Not investment advice.\n\nhttps://datacutoff.com/radar.h
 tml?nct=NCT06894511\nhttps://clinicaltrials.gov/study/NCT06894511
URL:https://datacutoff.com/radar.html?nct=NCT06894511
CATEGORIES:Oncology,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06991556-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20261203
DTEND;VALUE=DATE:20261204
SUMMARY:JSB462 readout (P2) · Novartis Pharmaceuticals $NVS
DESCRIPTION:An Open-label Study of JSB462 (Luxdegalutamide) in Combination 
 With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive 
 Prostate Cancer (mHSPC)\n\nPrimary completion date: 2026-12-03 (estimated)
 \nOriginally planned: 2032-03-30 (-63.9 months)\nPhase 2 · Oncology · Me
 tastatic Hormone-sensitive Prostate Cancer\nEnrollment: 168 · Sites: 64\n
 \nPrimary completion = last participant's primary-endpoint data collected\
 ; topline results usually follow weeks to months later. Sponsor-reported\,
  often an estimate. Not investment advice.\n\nhttps://trialsonar.netlify.a
 pp/radar.html?nct=NCT06991556\nhttps://clinicaltrials.gov/study/NCT0699155
 6
URL:https://datacutoff.com/radar.html?nct=NCT06991556
CATEGORIES:Oncology,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05849298-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20261223
DTEND;VALUE=DATE:20261224
SUMMARY:PSMACare readout (P2) · Novartis Pharmaceuticals $NVS
DESCRIPTION:A Phase II Study of AAA617 Alone and AAA617 in Combination With
  ARPI in Patients With PSMA PET Scan Positive CRPC\n\nPrimary completion d
 ate: 2026-12-23 (estimated)\nOriginally planned: 2028-11-10 (-22.6 months)
 \nPhase 2 · Oncology · Prostatic Neoplasm\nEnrollment: 49 · Sites: 31\n
 \nPrimary completion = last participant's primary-endpoint data collected\
 ; topline results usually follow weeks to months later. Sponsor-reported\,
  often an estimate. Not investment advice.\n\nhttps://trialsonar.netlify.a
 pp/radar.html?nct=NCT05849298\nhttps://clinicaltrials.gov/study/NCT0584929
 8
URL:https://datacutoff.com/radar.html?nct=NCT05849298
CATEGORIES:Oncology,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06388941-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Iptacopan readout (P2) · Novartis Pharmaceuticals $NVS
DESCRIPTION:Iptacopan in Patients With ANCA Associated Vasculitis\n\nPrimar
 y completion date: 2026-12-30 (estimated)\nOriginally planned: 2027-08-27 
 (-7.9 months)\nPhase 2 · Immuno · Anti-Neutrophil Cytoplasm Antibodies (
 ANCA) Associated Vasc…\nEnrollment: 84 · Sites: 40\n\nPrimary completio
 n = last participant's primary-endpoint data collected\; topline results u
 sually follow weeks to months later. Sponsor-reported\, often an estimate.
  Not investment advice.\n\nhttps://datacutoff.com/radar.html?nct=N
 CT06388941\nhttps://clinicaltrials.gov/study/NCT06388941
URL:https://datacutoff.com/radar.html?nct=NCT06388941
CATEGORIES:Immuno,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07102628-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270116
DTEND;VALUE=DATE:20270117
SUMMARY:ACS readout (P3) · Novartis Pharmaceuticals $NVS
DESCRIPTION:Evaluation of Efficacy and Safety of Early in Hospital Initiati
 on of Inclisiran Treatment in Patients With Acute Coronary Syndromes\n\nPr
 imary completion date: 2027-01-16 (estimated)\nOriginally planned: 2027-03
 -06 (-1.6 months)\nPhase 3 · Cardio-Met · Acute Coronary Syndrome\nEnrol
 lment: 305 · Sites: 65\n\nPrimary completion = last participant's primary
 -endpoint data collected\; topline results usually follow weeks to months 
 later. Sponsor-reported\, often an estimate. Not investment advice.\n\nhtt
 ps://trialsonar.netlify.app/radar.html?nct=NCT07102628\nhttps://clinicaltr
 ials.gov/study/NCT07102628
URL:https://datacutoff.com/radar.html?nct=NCT07102628
CATEGORIES:Cardio-Met,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05038735-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270128
DTEND;VALUE=DATE:20270129
SUMMARY:EPIK-B5 readout (P3) · Novartis Pharmaceuticals $NVS
DESCRIPTION:Study to Assess the Efficacy and Safety of Alpelisib Plus Fulve
 strant in Participants With HR-positive (HR+)\, HER2-negative\, Advanced B
 reast Cancer After Treatment With a CDK4/6 I…\n\nPrimary completion date
 : 2027-01-28 (estimated)\nOriginally planned: 2026-10-30 (+3.0 months)\nPh
 ase 3 · Oncology · Breast Cancer\nEnrollment: 210 · Sites: 68\n\nPrimar
 y completion = last participant's primary-endpoint data collected\; toplin
 e results usually follow weeks to months later. Sponsor-reported\, often a
 n estimate. Not investment advice.\n\nhttps://datacutoff.com/radar
 .html?nct=NCT05038735\nhttps://clinicaltrials.gov/study/NCT05038735
URL:https://datacutoff.com/radar.html?nct=NCT05038735
CATEGORIES:Oncology,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04544189-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270129
DTEND;VALUE=DATE:20270130
SUMMARY:Alpelisib readout (P2) · Novartis Pharmaceuticals $NVS
DESCRIPTION:Study Assessing the Efficacy and Safety of Treatment With Alpel
 isib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Chinese Men and P
 ostmenopausal Women With Advanced Breast C…\n\nPrimary completion date: 
 2027-01-29 (estimated)\nOriginally planned: 2023-11-13 (+38.5 months)\nPha
 se 2 · Oncology · Breast Neoplasms\nEnrollment: 69 · Sites: 24\n\nPrima
 ry completion = last participant's primary-endpoint data collected\; topli
 ne results usually follow weeks to months later. Sponsor-reported\, often 
 an estimate. Not investment advice.\n\nhttps://datacutoff.com/rada
 r.html?nct=NCT04544189\nhttps://clinicaltrials.gov/study/NCT04544189
URL:https://datacutoff.com/radar.html?nct=NCT04544189
CATEGORIES:Oncology,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04817618-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270129
DTEND;VALUE=DATE:20270130
SUMMARY:APPEAR-C3G readout (P3) · Novartis Pharmaceuticals $NVS
DESCRIPTION:Study of Efficacy and Safety of Iptacopan in Patients With C3 G
 lomerulopathy.\n\nPrimary completion date: 2027-01-29 (estimated)\nOrigina
 lly planned: 2023-07-19 (+42.4 months)\nPhase 3 · GI·Renal·Heme · C3G\
 nEnrollment: 98 · Sites: 88\n\nPrimary completion = last participant's pr
 imary-endpoint data collected\; topline results usually follow weeks to mo
 nths later. Sponsor-reported\, often an estimate. Not investment advice.\n
 \nhttps://datacutoff.com/radar.html?nct=NCT04817618\nhttps://clini
 caltrials.gov/study/NCT04817618
URL:https://datacutoff.com/radar.html?nct=NCT04817618
CATEGORIES:GI·Renal·Heme,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02934568-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:LEE011 readout (P2) · Novartis Pharmaceuticals $NVS
DESCRIPTION:Ribociclib (LEE011) Rollover Study for Continued Access\n\nPrim
 ary completion date: 2027-02-01 (estimated)\nOriginally planned: 2022-04 (
 +58.0 months)\nPhase 2 · Oncology · Continued Access to Study Treatment(
 s)\, Cancers With a Mass…\nEnrollment: 22 · Sites: 13\n\nPrimary comple
 tion = last participant's primary-endpoint data collected\; topline result
 s usually follow weeks to months later. Sponsor-reported\, often an estima
 te. Not investment advice.\n\nhttps://datacutoff.com/radar.html?nc
 t=NCT02934568\nhttps://clinicaltrials.gov/study/NCT02934568
URL:https://datacutoff.com/radar.html?nct=NCT02934568
CATEGORIES:Oncology,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04417621-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270202
DTEND;VALUE=DATE:20270203
SUMMARY:LXH254 readout (P2) · Novartis Pharmaceuticals $NVS
DESCRIPTION:Study of Efficacy and Safety of LXH254 Combinations in Patients
  With Previously Treated Unresectable or Metastatic Melanoma\n\nPrimary co
 mpletion date: 2027-02-02 (estimated)\nOriginally planned: 2023-04-27 (+45
 .2 months)\nPhase 2 · Oncology · Melanoma\nEnrollment: 134 · Sites: 36\
 n\nPrimary completion = last participant's primary-endpoint data collected
 \; topline results usually follow weeks to months later. Sponsor-reported\
 , often an estimate. Not investment advice.\n\nhttps://trialsonar.netlify.
 app/radar.html?nct=NCT04417621\nhttps://clinicaltrials.gov/study/NCT044176
 21
URL:https://datacutoff.com/radar.html?nct=NCT04417621
CATEGORIES:Oncology,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07811908-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270204
DTEND;VALUE=DATE:20270205
SUMMARY:PLATINUM readout (P2) · Novartis Pharmaceuticals $NVS
DESCRIPTION:Platform Study to Evaluate the Efficacy and Safety of Anti-mala
 rial Agents in Participants With Uncomplicated Plasmodium Falciparum Malar
 ia (Cohort C2)\n\nPrimary completion date: 2027-02-04 (estimated)\nPhase 2
  · Infectious · Uncomplicated Plasmodium Falciparum Malaria\nEnrollment:
  120 · Sites: 13\n\nPrimary completion = last participant's primary-endpo
 int data collected\; topline results usually follow weeks to months later.
  Sponsor-reported\, often an estimate. Not investment advice.\n\nhttps://t
 rialsonar.netlify.app/radar.html?nct=NCT07811908\nhttps://clinicaltrials.g
 ov/study/NCT07811908
URL:https://datacutoff.com/radar.html?nct=NCT07811908
CATEGORIES:Infectious,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06868212-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270222
DTEND;VALUE=DATE:20270223
SUMMARY:RECLAIM readout (P3) · Novartis Pharmaceuticals $NVS
DESCRIPTION:A Study to Evaluate Efficacy of Remibrutinib Compared to Dupilu
 mab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inade
 quately Controlled by Second Generation H1…\n\nPrimary completion date: 
 2027-02-22 (estimated)\nPhase 3 · Immuno · Chronic Spontaneous Urticaria
  (CSU)\nEnrollment: 409 · Sites: 121\n\nPrimary completion = last partici
 pant's primary-endpoint data collected\; topline results usually follow we
 eks to months later. Sponsor-reported\, often an estimate. Not investment 
 advice.\n\nhttps://datacutoff.com/radar.html?nct=NCT06868212\nhttp
 s://clinicaltrials.gov/study/NCT06868212
URL:https://datacutoff.com/radar.html?nct=NCT06868212
CATEGORIES:Immuno,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02962414-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270226
DTEND;VALUE=DATE:20270227
SUMMARY:everolimus readout (P3) · Novartis Pharmaceuticals $NVS
DESCRIPTION:Roll-over Study to Collect and Assess Long-term Safety of Evero
 limus in Patients With TSC and Refractory Seizures Who Have Completed the 
 EXIST-3 Study [CRAD001M2304] and Who Are B…\n\nPrimary completion date: 
 2027-02-26 (estimated)\nPhase 3 · Oncology · Tuberous Sclerosis Complex\
 nEnrollment: 206 · Sites: 68\n\nPrimary completion = last participant's p
 rimary-endpoint data collected\; topline results usually follow weeks to m
 onths later. Sponsor-reported\, often an estimate. Not investment advice.\
 n\nhttps://datacutoff.com/radar.html?nct=NCT02962414\nhttps://clin
 icaltrials.gov/study/NCT02962414
URL:https://datacutoff.com/radar.html?nct=NCT02962414
CATEGORIES:Oncology,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04208178-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270226
DTEND;VALUE=DATE:20270227
SUMMARY:EPIK-B2 readout (P3) · Novartis Pharmaceuticals $NVS
DESCRIPTION:Study of Alpelisib (BYL719) in Combination With Trastuzumab and
  Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced
  Breast Cancer With a PIK3CA Mutation\n\nPrimary completion date: 2027-02-
 26 (estimated)\nOriginally planned: 2024-04-02 (+34.8 months)\nPhase 3 · 
 Oncology · Advanced HER2+Breast Cancer\nEnrollment: 19 · Sites: 11\n\nPr
 imary completion = last participant's primary-endpoint data collected\; to
 pline results usually follow weeks to months later. Sponsor-reported\, oft
 en an estimate. Not investment advice.\n\nhttps://datacutoff.com/r
 adar.html?nct=NCT04208178\nhttps://clinicaltrials.gov/study/NCT04208178
URL:https://datacutoff.com/radar.html?nct=NCT04208178
CATEGORIES:Oncology,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04524000-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270226
DTEND;VALUE=DATE:20270227
SUMMARY:Alpelisib readout (P2) · Novartis Pharmaceuticals $NVS
DESCRIPTION:Study Assessing the Efficacy and Safety of Treatment With Alpel
 isib Plus Fulvestrant in Japanese Men and Postmenopausal Women With Advanc
 ed Breast Cancer\n\nPrimary completion date: 2027-02-26 (estimated)\nOrigi
 nally planned: 2023-06-30 (+43.9 months)\nPhase 2 · Oncology · Advanced 
 Breast Cancer\nEnrollment: 24 · Sites: 15\n\nPrimary completion = last pa
 rticipant's primary-endpoint data collected\; topline results usually foll
 ow weeks to months later. Sponsor-reported\, often an estimate. Not invest
 ment advice.\n\nhttps://datacutoff.com/radar.html?nct=NCT04524000\
 nhttps://clinicaltrials.gov/study/NCT04524000
URL:https://datacutoff.com/radar.html?nct=NCT04524000
CATEGORIES:Oncology,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07249463-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270323
DTEND;VALUE=DATE:20270324
SUMMARY:CRYPTONITE readout (P2) · Novartis Pharmaceuticals $NVS
DESCRIPTION:Study Testing the Efficacy\, Safety\, and Tolerability of EDI04
 8 in Cryptosporidium Infection Model in Healthy Adults\n\nPrimary completi
 on date: 2027-03-23 (estimated)\nPhase 2 · Infectious · Cryptosporidiosi
 s\nEnrollment: 80 · Sites: 2\n\nPrimary completion = last participant's p
 rimary-endpoint data collected\; topline results usually follow weeks to m
 onths later. Sponsor-reported\, often an estimate. Not investment advice.\
 n\nhttps://datacutoff.com/radar.html?nct=NCT07249463\nhttps://clin
 icaltrials.gov/study/NCT07249463
URL:https://datacutoff.com/radar.html?nct=NCT07249463
CATEGORIES:Infectious,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05639114-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270326
DTEND;VALUE=DATE:20270327
SUMMARY:SIRIUS-SLE 1 readout (P3) · Novartis Pharmaceuticals $NVS
DESCRIPTION:Phase 3 Study to Evaluate Two Regimens of Ianalumab on Top of S
 tandard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIR
 IUS-SLE 1)\n\nPrimary completion date: 2027-03-26 (estimated)\nOriginally 
 planned: 2027-01-19 (+2.2 months)\nPhase 3 · Immuno · Systemic Lupus Ery
 thematosus\nEnrollment: 436 · Sites: 135\n\nPrimary completion = last par
 ticipant's primary-endpoint data collected\; topline results usually follo
 w weeks to months later. Sponsor-reported\, often an estimate. Not investm
 ent advice.\n\nhttps://datacutoff.com/radar.html?nct=NCT05639114\n
 https://clinicaltrials.gov/study/NCT05639114
URL:https://datacutoff.com/radar.html?nct=NCT05639114
CATEGORIES:Immuno,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04094311-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:CTL019 readout (P3) · Novartis Pharmaceuticals $NVS
DESCRIPTION:Study of Out of Specification for Tisagenlecleucel\n\nPrimary c
 ompletion date: 2027-03-31 (estimated)\nOriginally planned: 2022-03-31 (+6
 0.0 months)\nPhase 3 · Oncology · B-cell Acute Lymphoblastic Leukemia\, 
 Diffuse Large B-cell Lymphoma\nEnrollment: 200 · Sites: 55\n\nPrimary com
 pletion = last participant's primary-endpoint data collected\; topline res
 ults usually follow weeks to months later. Sponsor-reported\, often an est
 imate. Not investment advice.\n\nhttps://datacutoff.com/radar.html
 ?nct=NCT04094311\nhttps://clinicaltrials.gov/study/NCT04094311
URL:https://datacutoff.com/radar.html?nct=NCT04094311
CATEGORIES:Oncology,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05624749-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270412
DTEND;VALUE=DATE:20270413
SUMMARY:SIRIUS-SLE 2 readout (P3) · Novartis Pharmaceuticals $NVS
DESCRIPTION:Phase 3 Study to Evaluate Ianalumab on Top of Standard-of-care 
 Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2)\n\nPr
 imary completion date: 2027-04-12 (estimated)\nOriginally planned: 2027-01
 -26 (+2.5 months)\nPhase 3 · Immuno · Systemic Lupus Erythematosus\nEnro
 llment: 288 · Sites: 90\n\nPrimary completion = last participant's primar
 y-endpoint data collected\; topline results usually follow weeks to months
  later. Sponsor-reported\, often an estimate. Not investment advice.\n\nht
 tps://trialsonar.netlify.app/radar.html?nct=NCT05624749\nhttps://clinicalt
 rials.gov/study/NCT05624749
URL:https://datacutoff.com/radar.html?nct=NCT05624749
CATEGORIES:Immuno,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07203001-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270422
DTEND;VALUE=DATE:20270423
SUMMARY:MAS825 readout (P2) · Novartis Pharmaceuticals $NVS
DESCRIPTION:A Phase II Trial to Evaluate the Clinical Efficacy\, Safety and
  Tolerability of MAS825 in Pediatric and Adult Participants With Still's D
 isease\n\nPrimary completion date: 2027-04-22 (estimated)\nOriginally plan
 ned: 2029-05-02 (-24.3 months)\nPhase 2 · Immuno · Still´s Disease\nEnr
 ollment: 30 · Sites: 24\n\nPrimary completion = last participant's primar
 y-endpoint data collected\; topline results usually follow weeks to months
  later. Sponsor-reported\, often an estimate. Not investment advice.\n\nht
 tps://trialsonar.netlify.app/radar.html?nct=NCT07203001\nhttps://clinicalt
 rials.gov/study/NCT07203001
URL:https://datacutoff.com/radar.html?nct=NCT07203001
CATEGORIES:Immuno,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07235046-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270426
DTEND;VALUE=DATE:20270427
SUMMARY:DII235 readout (P2) · Novartis Pharmaceuticals $NVS
DESCRIPTION:A Study of DII235 in Adults With Elevated Lipoprotein(a)\n\nPri
 mary completion date: 2027-04-26 (estimated)\nOriginally planned: 2027-09-
 08 (-4.4 months)\nPhase 2 · Cardio-Met · Lipoprotein Disorder\nEnrollmen
 t: 234 · Sites: 63\n\nPrimary completion = last participant's primary-end
 point data collected\; topline results usually follow weeks to months late
 r. Sponsor-reported\, often an estimate. Not investment advice.\n\nhttps:/
 /trialsonar.netlify.app/radar.html?nct=NCT07235046\nhttps://clinicaltrials
 .gov/study/NCT07235046
URL:https://datacutoff.com/radar.html?nct=NCT07235046
CATEGORIES:Cardio-Met,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07610278-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270428
DTEND;VALUE=DATE:20270429
SUMMARY:QCZ484 readout (P2) · Novartis Pharmaceuticals $NVS
DESCRIPTION:A Study to Evaluate the Pharmacodynamics of a Combination of QC
 Z484 and Inclisiran in Participants With Hypertension and Concomitant Hype
 rcholesterolemia\n\nPrimary completion date: 2027-04-28 (estimated)\nPhase
  2 · Cardio-Met · Hypercholesterolaemia\nEnrollment: 120 · Sites: 29\n\
 nPrimary completion = last participant's primary-endpoint data collected\;
  topline results usually follow weeks to months later. Sponsor-reported\, 
 often an estimate. Not investment advice.\n\nhttps://trialsonar.netlify.ap
 p/radar.html?nct=NCT07610278\nhttps://clinicaltrials.gov/study/NCT07610278
URL:https://datacutoff.com/radar.html?nct=NCT07610278
CATEGORIES:Cardio-Met,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06517758-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Iptacopan readout (P3) · Novartis Pharmaceuticals $NVS
DESCRIPTION:A Phase III Study to Investigate Efficacy\, Safety and Tolerabi
 lity of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Year
 s With gMG.\n\nPrimary completion date: 2027-04-30 (estimated)\nOriginally
  planned: 2026-12-28 (+4.0 months)\nPhase 3 · Oncology · Generalized Mya
 sthenia Gravis\nEnrollment: 146 · Sites: 116\n\nPrimary completion = last
  participant's primary-endpoint data collected\; topline results usually f
 ollow weeks to months later. Sponsor-reported\, often an estimate. Not inv
 estment advice.\n\nhttps://datacutoff.com/radar.html?nct=NCT065177
 58\nhttps://clinicaltrials.gov/study/NCT06517758
URL:https://datacutoff.com/radar.html?nct=NCT06517758
CATEGORIES:Oncology,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05030428-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270510
DTEND;VALUE=DATE:20270511
SUMMARY:VICTORION-2P readout (P3) · Novartis Pharmaceuticals $NVS
DESCRIPTION:Study of Inclisiran to Prevent Cardiovascular (CV) Events in Pa
 rticipants With Established Cardiovascular Disease\n\nPrimary completion d
 ate: 2027-05-10 (estimated)\nOriginally planned: 2027-01-04 (+4.1 months)\
 nPhase 3 · Cardio-Met · Atherosclerotic Cardiovascular Disease\nEnrollme
 nt: 17004 · Sites: 989\n\nPrimary completion = last participant's primary
 -endpoint data collected\; topline results usually follow weeks to months 
 later. Sponsor-reported\, often an estimate. Not investment advice.\n\nhtt
 ps://trialsonar.netlify.app/radar.html?nct=NCT05030428\nhttps://clinicaltr
 ials.gov/study/NCT05030428
URL:https://datacutoff.com/radar.html?nct=NCT05030428
CATEGORIES:Cardio-Met,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06799000-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270517
DTEND;VALUE=DATE:20270518
SUMMARY:Remibrutinib Dose A readout (P3) · Novartis Pharmaceuticals $NVS
DESCRIPTION:A Phase 3 Study to Assess Efficacy Safety and Tolerability of R
 emibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidra
 denitis Suppurativa (RECHARGE 1)\n\nPrimary completion date: 2027-05-17 (e
 stimated)\nOriginally planned: 2028-09-21 (-16.2 months)\nPhase 3 · Infec
 tious · Hidradenitis Suppurativa\nEnrollment: 588 · Sites: 139\n\nPrimar
 y completion = last participant's primary-endpoint data collected\; toplin
 e results usually follow weeks to months later. Sponsor-reported\, often a
 n estimate. Not investment advice.\n\nhttps://datacutoff.com/radar
 .html?nct=NCT06799000\nhttps://clinicaltrials.gov/study/NCT06799000
URL:https://datacutoff.com/radar.html?nct=NCT06799000
CATEGORIES:Infectious,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07220577-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270517
DTEND;VALUE=DATE:20270518
SUMMARY:GIA632 readout (P2) · Novartis Pharmaceuticals $NVS
DESCRIPTION:Phase 2a Study to Assess the Efficacy\,Safety and Tolerability 
 of GIA632 in Adult Participants With Moderate to Severe Atopic Dermatitis\
 n\nPrimary completion date: 2027-05-17 (estimated)\nPhase 2 · Immuno · A
 topic Dermatitis\nEnrollment: 34 · Sites: 28\n\nPrimary completion = last
  participant's primary-endpoint data collected\; topline results usually f
 ollow weeks to months later. Sponsor-reported\, often an estimate. Not inv
 estment advice.\n\nhttps://datacutoff.com/radar.html?nct=NCT072205
 77\nhttps://clinicaltrials.gov/study/NCT07220577
URL:https://datacutoff.com/radar.html?nct=NCT07220577
CATEGORIES:Immuno,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06840392-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270603
DTEND;VALUE=DATE:20270604
SUMMARY:RECHARGE-2 readout (P3) · Novartis Pharmaceuticals $NVS
DESCRIPTION:A Phase 3 Study to Assess Efficacy Safety and Tolerability of R
 emibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidra
 denitis Suppurativa\n\nPrimary completion date: 2027-06-03 (estimated)\nOr
 iginally planned: 2028-06-02 (-12.0 months)\nPhase 3 · Infectious · Hidr
 adenitis Suppurativa\nEnrollment: 565 · Sites: 129\n\nPrimary completion 
 = last participant's primary-endpoint data collected\; topline results usu
 ally follow weeks to months later. Sponsor-reported\, often an estimate. N
 ot investment advice.\n\nhttps://datacutoff.com/radar.html?nct=NCT
 06840392\nhttps://clinicaltrials.gov/study/NCT06840392
URL:https://datacutoff.com/radar.html?nct=NCT06840392
CATEGORIES:Infectious,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04980833-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270622
DTEND;VALUE=DATE:20270623
SUMMARY:EPIK-P3 readout (P2) · Novartis Pharmaceuticals $NVS
DESCRIPTION:Study Assessing Long-term Safety and Efficacy of Alpelisib in P
 atients With PIK3CA-Related Overgrowth Spectrum (PROS) Who Previously Part
 icipated in Study CBYL719F12002 (EPIK-P1)\n\nPrimary completion date: 2027
 -06-22 (estimated)\nOriginally planned: 2027-10-27 (-4.2 months)\nPhase 2 
 · Other · PIK3CA-related Overgrowth Spectrum (PROS)\nEnrollment: 41 · S
 ites: 6\n\nPrimary completion = last participant's primary-endpoint data c
 ollected\; topline results usually follow weeks to months later. Sponsor-r
 eported\, often an estimate. Not investment advice.\n\nhttps://trialsonar.
 netlify.app/radar.html?nct=NCT04980833\nhttps://clinicaltrials.gov/study/N
 CT04980833
URL:https://datacutoff.com/radar.html?nct=NCT04980833
CATEGORIES:Other,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07047118-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270716
DTEND;VALUE=DATE:20270717
SUMMARY:JSB462 readout (P2) · Novartis Pharmaceuticals $NVS
DESCRIPTION:A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipiv
 otide Tetraxetan in Patients With Metastatic Castration Resistant Prostate
  Cancer (mCRPC)\n\nPrimary completion date: 2027-07-16 (estimated)\nOrigin
 ally planned: 2028-02-14 (-7.0 months)\nPhase 2 · Oncology · Prostatic C
 ancer\, Castration-Resistant\nEnrollment: 138 · Sites: 44\n\nPrimary comp
 letion = last participant's primary-endpoint data collected\; topline resu
 lts usually follow weeks to months later. Sponsor-reported\, often an esti
 mate. Not investment advice.\n\nhttps://datacutoff.com/radar.html?
 nct=NCT07047118\nhttps://clinicaltrials.gov/study/NCT07047118
URL:https://datacutoff.com/radar.html?nct=NCT07047118
CATEGORIES:Oncology,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06006559-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270722
DTEND;VALUE=DATE:20270723
SUMMARY:EYU688 readout (P2) · Novartis Pharmaceuticals $NVS
DESCRIPTION:A Study to Assess the Efficacy\, Safety and Pharmacokinetics of
  EYU688 in Patients With Dengue Fever\n\nPrimary completion date: 2027-07-
 22 (estimated)\nOriginally planned: 2024-10-08 (+33.4 months)\nPhase 2 · 
 Infectious · Dengue\nEnrollment: 108 · Sites: 27\n\nPrimary completion =
  last participant's primary-endpoint data collected\; topline results usua
 lly follow weeks to months later. Sponsor-reported\, often an estimate. No
 t investment advice.\n\nhttps://datacutoff.com/radar.html?nct=NCT0
 6006559\nhttps://clinicaltrials.gov/study/NCT06006559
URL:https://datacutoff.com/radar.html?nct=NCT06006559
CATEGORIES:Infectious,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06632600-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270722
DTEND;VALUE=DATE:20270723
SUMMARY:LXE408 readout (P2) · Novartis Pharmaceuticals $NVS
DESCRIPTION:A Study of Efficacy\, Safety\, Tolerability of LXE408 in Partic
 ipants With Chronic Chagas Disease.\n\nPrimary completion date: 2027-07-22
  (estimated)\nPhase 2 · Infectious · Chagas Disease\nEnrollment: 130 · 
 Sites: 22\n\nPrimary completion = last participant's primary-endpoint data
  collected\; topline results usually follow weeks to months later. Sponsor
 -reported\, often an estimate. Not investment advice.\n\nhttps://trialsona
 r.netlify.app/radar.html?nct=NCT06632600\nhttps://clinicaltrials.gov/study
 /NCT06632600
URL:https://datacutoff.com/radar.html?nct=NCT06632600
CATEGORIES:Infectious,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07467993-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270729
DTEND;VALUE=DATE:20270730
SUMMARY:STAR-1 readout (P2) · Novartis Pharmaceuticals $NVS
DESCRIPTION:Study to Assess the Safety\, Tolerability\, and Treatment Respo
 nse of GXV813 in Hospitalized Adults With Schizophrenia\n\nPrimary complet
 ion date: 2027-07-29 (estimated)\nOriginally planned: 2027-04-27 (+3.1 mon
 ths)\nPhase 2 · Neuro · Schizophrenia\nEnrollment: 142 · Sites: 16\n\nP
 rimary completion = last participant's primary-endpoint data collected\; t
 opline results usually follow weeks to months later. Sponsor-reported\, of
 ten an estimate. Not investment advice.\n\nhttps://datacutoff.com/
 radar.html?nct=NCT07467993\nhttps://clinicaltrials.gov/study/NCT07467993
URL:https://datacutoff.com/radar.html?nct=NCT07467993
CATEGORIES:Neuro,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03040973-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270730
DTEND;VALUE=DATE:20270731
SUMMARY:Capmatinib readout (P2) · Novartis Pharmaceuticals $NVS
DESCRIPTION:Study to Allow Patients Previously Participating in a Novartis 
 Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent
  or in Combination With Other Treatments o…\n\nPrimary completion date: 
 2027-07-30 (estimated)\nOriginally planned: 2019-04 (+99.9 months)\nPhase 
 2 · Oncology · Advanced Solid Tumors Which Are cMET-dependent\nEnrollmen
 t: 29 · Sites: 15\n\nPrimary completion = last participant's primary-endp
 oint data collected\; topline results usually follow weeks to months later
 . Sponsor-reported\, often an estimate. Not investment advice.\n\nhttps://
 trialsonar.netlify.app/radar.html?nct=NCT03040973\nhttps://clinicaltrials.
 gov/study/NCT03040973
URL:https://datacutoff.com/radar.html?nct=NCT03040973
CATEGORIES:Oncology,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05222529-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270730
DTEND;VALUE=DATE:20270731
SUMMARY:Glycopyrronium bromide 25ug readout (P2) · Novartis Pharmaceutical
 s $NVS
DESCRIPTION:Pharmacokinetics\, Pharmacodynamics\, Safety and Tolerability o
 f Glycopyrronium (Bromide) in Children (6 to Less Than 12 Years) With Asth
 ma\n\nPrimary completion date: 2027-07-30 (estimated)\nOriginally planned:
  2024-02-02 (+41.9 months)\nPhase 2 · Respiratory · Asthma\nEnrollment: 
 42 · Sites: 23\n\nPrimary completion = last participant's primary-endpoin
 t data collected\; topline results usually follow weeks to months later. S
 ponsor-reported\, often an estimate. Not investment advice.\n\nhttps://tri
 alsonar.netlify.app/radar.html?nct=NCT05222529\nhttps://clinicaltrials.gov
 /study/NCT05222529
URL:https://datacutoff.com/radar.html?nct=NCT05222529
CATEGORIES:Respiratory,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06470048-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270730
DTEND;VALUE=DATE:20270731
SUMMARY:Ianalumab readout (P2) · Novartis Pharmaceuticals $NVS
DESCRIPTION:A Clinical Study to Evaluate Ianalumab in Participants With Dif
 fuse Cutaneous Systemic Sclerosis\n\nPrimary completion date: 2027-07-30 (
 estimated)\nOriginally planned: 2028-07-10 (-11.4 months)\nPhase 2 · Immu
 no · Diffuse Cutaneous Systemic Sclerosis\nEnrollment: 203 · Sites: 96\n
 \nPrimary completion = last participant's primary-endpoint data collected\
 ; topline results usually follow weeks to months later. Sponsor-reported\,
  often an estimate. Not investment advice.\n\nhttps://trialsonar.netlify.a
 pp/radar.html?nct=NCT06470048\nhttps://clinicaltrials.gov/study/NCT0647004
 8
URL:https://datacutoff.com/radar.html?nct=NCT06470048
CATEGORIES:Immuno,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05852938-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270810
DTEND;VALUE=DATE:20270811
SUMMARY:BION-1301 readout (P3) · Novartis Pharmaceuticals $NVS
DESCRIPTION:A Study of Zigakibart in Adults With IgA Nephropathy\n\nPrimary
  completion date: 2027-08-10 (estimated)\nOriginally planned: 2026-07-01 (
 +13.3 months)\nPhase 3 · GI·Renal·Heme · IgA Nephropathy\, Immunoglobu
 lin A Nephropathy\nEnrollment: 383 · Sites: 200\n\nPrimary completion = l
 ast participant's primary-endpoint data collected\; topline results usuall
 y follow weeks to months later. Sponsor-reported\, often an estimate. Not 
 investment advice.\n\nhttps://datacutoff.com/radar.html?nct=NCT058
 52938\nhttps://clinicaltrials.gov/study/NCT05852938
URL:https://datacutoff.com/radar.html?nct=NCT05852938
CATEGORIES:GI·Renal·Heme,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07830719-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270815
DTEND;VALUE=DATE:20270816
SUMMARY:YMI024 readout (P2) · Novartis Pharmaceuticals $NVS
DESCRIPTION:Dose-finding Study of YMI024 to Assess Efficacy\, Safety\, and 
 Tolerability in Adults With Stable Coronary Artery Disease and Elevated hs
 CRP\n\nPrimary completion date: 2027-08-15 (estimated)\nOriginally planned
 : 2027-09-16 (-1.1 months)\nPhase 2 · Cardio-Met · Coronary Artery Disea
 se\nEnrollment: 180 · Sites: 23\n\nPrimary completion = last participant'
 s primary-endpoint data collected\; topline results usually follow weeks t
 o months later. Sponsor-reported\, often an estimate. Not investment advic
 e.\n\nhttps://datacutoff.com/radar.html?nct=NCT07830719\nhttps://c
 linicaltrials.gov/study/NCT07830719
URL:https://datacutoff.com/radar.html?nct=NCT07830719
CATEGORIES:Cardio-Met,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06865651-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270823
DTEND;VALUE=DATE:20270824
SUMMARY:Remibrutinib readout (P2) · Novartis Pharmaceuticals $NVS
DESCRIPTION:Study of Remibrutinib (LOU064) Efficacy and Safety and Explorat
 ion of Its Mechanism of Action in Participants With Chronic Urticaria\n\nP
 rimary completion date: 2027-08-23 (estimated)\nOriginally planned: 2027-0
 6-21 (+2.1 months)\nPhase 2 · Immuno · Chronic Urticaria (CU): Chronic I
 nducible Urticaria (CINDU)…\nEnrollment: 44 · Sites: 17\n\nPrimary comp
 letion = last participant's primary-endpoint data collected\; topline resu
 lts usually follow weeks to months later. Sponsor-reported\, often an esti
 mate. Not investment advice.\n\nhttps://datacutoff.com/radar.html?
 nct=NCT06865651\nhttps://clinicaltrials.gov/study/NCT06865651
URL:https://datacutoff.com/radar.html?nct=NCT06865651
CATEGORIES:Immuno,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07217067-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270909
DTEND;VALUE=DATE:20270910
SUMMARY:PKN605 readout (P2) · Novartis Pharmaceuticals $NVS
DESCRIPTION:A Study to Investigate the Efficacy\, Safety\, Tolerability and
  Pharmacokinetics of PKN605 in Participants With Atrial Fibrillation\n\nPr
 imary completion date: 2027-09-09 (estimated)\nPhase 2 · Cardio-Met · At
 rial Fibrillation\nEnrollment: 165 · Sites: 40\n\nPrimary completion = la
 st participant's primary-endpoint data collected\; topline results usually
  follow weeks to months later. Sponsor-reported\, often an estimate. Not i
 nvestment advice.\n\nhttps://datacutoff.com/radar.html?nct=NCT0721
 7067\nhttps://clinicaltrials.gov/study/NCT07217067
URL:https://datacutoff.com/radar.html?nct=NCT07217067
CATEGORIES:Cardio-Met,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05126277-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270921
DTEND;VALUE=DATE:20270922
SUMMARY:SIRIUS-LN readout (P3) · Novartis Pharmaceuticals $NVS
DESCRIPTION:Safety\, Efficacy and Tolerability of Ianalumab Versus Placebo\
 , Combination With SoC Therapy\, in Participants With Active Lupus Nephrit
 is\n\nPrimary completion date: 2027-09-21 (estimated)\nOriginally planned:
  2025-04-25 (+28.9 months)\nPhase 3 · Immuno · Lupus Nephritis\nEnrollme
 nt: 452 · Sites: 145\n\nPrimary completion = last participant's primary-e
 ndpoint data collected\; topline results usually follow weeks to months la
 ter. Sponsor-reported\, often an estimate. Not investment advice.\n\nhttps
 ://trialsonar.netlify.app/radar.html?nct=NCT05126277\nhttps://clinicaltria
 ls.gov/study/NCT05126277
URL:https://datacutoff.com/radar.html?nct=NCT05126277
CATEGORIES:Immuno,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04747613-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20271018
DTEND;VALUE=DATE:20271019
SUMMARY:Iptacopan readout (P3) · Novartis Pharmaceuticals $NVS
DESCRIPTION:Long-term Safety and Tolerability of Iptacopan in Patients With
  Paroxysmal Nocturnal Hemoglobinuria\n\nPrimary completion date: 2027-10-1
 8 (estimated)\nOriginally planned: 2026-06-02 (+16.5 months)\nPhase 3 · G
 I·Renal·Heme · Paroxysmal Nocturnal Hemoglobinuria\nEnrollment: 208 · 
 Sites: 60\n\nPrimary completion = last participant's primary-endpoint data
  collected\; topline results usually follow weeks to months later. Sponsor
 -reported\, often an estimate. Not investment advice.\n\nhttps://trialsona
 r.netlify.app/radar.html?nct=NCT04747613\nhttps://clinicaltrials.gov/study
 /NCT04747613
URL:https://datacutoff.com/radar.html?nct=NCT04747613
CATEGORIES:GI·Renal·Heme,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03876769-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20271019
DTEND;VALUE=DATE:20271020
SUMMARY:CASSIOPEIA readout (P2) · Novartis Pharmaceuticals $NVS
DESCRIPTION:Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EO
 C MRD Positive Patients\n\nPrimary completion date: 2027-10-19 (estimated)
 \nOriginally planned: 2026-11-26 (+10.7 months)\nPhase 2 · Oncology · B-
 Cell Acute Lymphoblastic Leukemia\nEnrollment: 121 · Sites: 43\n\nPrimary
  completion = last participant's primary-endpoint data collected\; topline
  results usually follow weeks to months later. Sponsor-reported\, often an
  estimate. Not investment advice.\n\nhttps://datacutoff.com/radar.
 html?nct=NCT03876769\nhttps://clinicaltrials.gov/study/NCT03876769
URL:https://datacutoff.com/radar.html?nct=NCT03876769
CATEGORIES:Oncology,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
